Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Kolten Bush

Nurse Practitioner North Venice, FL Nurse Practitioner

NPI 1245982750 CMS profile 11352334

200 Healthcare Way Unit 103, North Venice, FL 34275

Open in the dashboard

General payments

$2,954

114 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kolten Bush of North Venice, FL is reported in the CMS Open Payments database as having received $2,954 across 114 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $837 32
2024 General $792 35
2023 General $765 27
2022 General $560 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kolten Bush
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Kolten Bush were reported at $837. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Kolten Bush Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $0 $135 $40–$426 $132
2022 $560 $152 $48–$470 $149
2023 $765 $166 $54–$529 $160
2024 $792 $173 $55–$556 $164
2025 $837 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $890 31 payments
  2. Boston Scientific Corporation $415 5 payments
  3. Novartis Pharmaceuticals Corporation $341 16 payments
  4. Pfizer Inc. $251 12 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $184 8 payments
  6. Alnylam Pharmaceuticals Inc. $175 7 payments
  7. Amgen Inc. $139 8 payments
  8. Actelion Pharmaceuticals US, Inc. $125 5 payments
  9. Merck Sharp & Dohme Corporation $123 6 payments
  10. E.R. Squibb & Sons, L.L.C. $73 3 payments
  11. Other $238 13 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $2,954 114 payments
Products named General payments · program years 2022–2025
  1. LifeVest $890 31 payments
  2. WATCHMAN Access System $399 4 payments
  3. LEQVIO $308 14 payments
  4. ONPATTRO $175 7 payments
  5. VYNDAQEL $148 7 payments
  6. Repatha $139 8 payments
  7. ENTRESTO $139 6 payments
  8. UPTRAVI $125 5 payments
  9. OPSUMIT $125 5 payments
  10. VERQUVO $123 6 payments
  11. Other $751 38 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

589

Median for Nurse Practitioner: 389

Drug cost

$360,701

Median for Nurse Practitioner: $21,885

Branded share of claims

23.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vyndaqel Tafamidis Meglumine Brand 12 $268,066
Eliquis Apixaban Brand 56 $56,489
Brilinta Ticagrelor Brand 33 $29,648
Metoprolol Succinate Generic 87 $1,495
Flecainide Acetate Generic 20 $1,142
Atorvastatin Calcium Generic 68 $751
Valsartan Generic 16 $452
Potassium Chloride Generic 34 $427
Clopidogrel Clopidogrel Bisulfate Brand 40 $393
Carvedilol Generic 30 $353

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $79
$79 — —
VYNDAQEL
  • PFIZER INC. $78
$78 12 —
ONPATTRO
  • Alnylam Pharmaceuticals Inc. $71
$71 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $71
$71 — —
Repatha
  • Amgen Inc. $48
$48 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

114 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record